

**RECORDATI: 2017 CORPORATE EVENTS' CALENDAR and DISCLOSURE OF QUARTERLY REPORTS**

Milan, 14 December 2016 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2017:

- |                   |  |
|-------------------|--|
| <b>9 February</b> | Board of Directors' meeting to approve the 2016 preliminary consolidated results as well as to approve the 2017-2019 business plan.<br><br>Presentation to financial analysts. |
| <b>1 March</b>    | Board of Directors' meeting to approve the 2016 consolidated financial statements and the draft of Recordati S.p.A.'s 2016 financial statements.                               |
| <b>11 April</b>   | Annual Shareholders' Meeting to approve the 2016 financial statements.   |
| <b>4 May</b>      | Board of Directors' meeting to approve the 2017 first quarter interim management statement.  |
| <b>27 July</b>    | Board of Directors' meeting to approve the 2017 half-yearly report.  |
| <b>26 October</b> | Board of Directors' meeting to approve the 2017 first nine months' interim management statement.   |

Recordati S.p.A. announces that the payment of the balance of the 2016 financial year dividend is planned for 26 April 2017, on each outstanding share at 24 April 2017 (ex-dividend date) and record date 25 April 2017, while payment of the interim dividend for the 2017 financial year is planned for 22 November 2017, on each outstanding share at 20 November 2017 (ex-dividend date) and record date 21 November 2017.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

\*

**Disclosure of quarterly reports**

Within the framework of the new relevant set of regulations<sup>1</sup>, in order to ensure continuity and regularity of information to its stakeholders and to the financial community, Recordati S.p.A. has decided to continue disclosing the quarterly reports, on a voluntary basis and until any different decision is taken

---

<sup>1</sup> Italian Legislative Decree n. 25/2016, enacting Directive 2013/50/EU, eliminated the mandatory requirement to disclose the interim financial report, previously requested pursuant to paragraph 5, art.154-ter of Italian Legislative Decree n. 58/1998. On 26 October 2016, CONSOB, by way of resolution n.19770, introduced some regulation amendments, including the new art.82-ter, which will come into force as of 2 January 2017.

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.  
REG. IMP. MILANO N. 00748210150  
CODICE FISCALE/P.IVA 007482210150  
R.E.A. MILANO N. 401832

in this respect, as already done during the year 2016, with comparable form and content to those of the previous financial years:

- the quarterly reports will be therefore disclosed by means of a press release which will be issued upon the conclusion of the meeting of the board of directors which approves the relative accounting information and by publishing the quarterly financial reports, following the meeting of the board of directors which approves the relative accounting information. As already stated, there will be no changes in the contents of such quarterly reports, as compared to those included in the quarterly reports so far disclosed;
- the quarterly reports will be subject to approval by the board of directors in meetings to be held within 45 days from the end of the first and third quarter of each year – that will be disclosed in the calendar of each financial year - and disclosed as above-mentioned and, in any case, within 45 days from the end of the first and third quarter of each year;
- the quarterly financial reports will continue to be published on the corporate website of Recordati S.p.A..

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2015 was € 1,047.7 million, operating income was € 278.5 million and net income was € 198.8 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

Investor Relations

Marianne Tatschke  
(39)0248787393  
e-mail: [inver@recordati.it](mailto:inver@recordati.it)

Media Relations

Studio Noris Morano  
(39)0276004736, (39)0276004745  
e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

*Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.*